This week, we continue our discussion of colorectal cancer, turning our attention to metastatic disease, specifically for cancers without targetable mutations. If you have not done already, we highly recommend you check out episode 104 for our GI oncology pharmacology discussion!Contents: - What information do we need when we approach a new patient with metastatic colorectal cancer? - How did we get to our current treatment paradigm? - Is there a role for maintenance 5-FU?- What is the role of EGFR-inhibitor bevacizumab?- Why does mutational analysis matter? - Why does sidedness of the tumor matter?- Is there a role for treatment holidays?- What do we do at the time of disease progression?**This episode is sponsored by our Global Research Partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related